Abstract The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan-Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemoendocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P \ 0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P \ 0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258-0.765) and DSS (P \ 0.001, HR 0.135, 95%CI 0.054-0.337). Thus, we focused on ERpositive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306-0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130-0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.
Introduction
Increasing data support a possible role of the androgen receptor (AR) as a marker of prognosis [1, 2] , particularly among patients with estrogen receptor (ER) positive breast cancer [3] . AR are frequently expressed together with ER and progesterone receptor (PgR) in well differentiated breast cancer [4] [5] [6] , but are rarely present in human epidermal growth factor receptor 2 (HER2) positive tumors [7, 8] . Specific cancer histotypes, such as the apocrine carcinoma, consistently express AR [9, 10] . Despite being ER and PgR-negative, and AR expression has been reported in about 45% of triple negative breast cancers [4, 8] . Studies using different analytical procedures, such as a binding assay [11] , immunohistochemistry (IHC) [3, 12] and reverse-phase protein arrays [13] , have suggested a possible role of AR to predict responsiveness to endocrine therapy. The impact of AR expression on survival of patients with high-risk ER-positive breast cancer, such as luminal B breast cancer [14] [15] [16] , has never been evaluated. However, it has been shown that in metastatic breast cancers, the median survival after disease recurrence of patients with AR-expressing tumors was significantly longer compared to that of patients with AR-negative tumors [2] .
In this study, we evaluated the prognostic value of AR in a large series of patients with ER-positive breast cancer after long follow-up. All patients were treated with endocrine therapy, with or without addition of chemotherapy. In particular, we focused on a subset of patients with tumors closely similar to luminal type B by conventional markers [17] and considered as more clinically aggressive than the luminal type A ER-positive breast cancers.
Patients and methods

Study design
A consecutive series of 953 patients diagnosed with ER-positive breast cancer between 1998 and 2003 was retrieved from the files of the Pathology Departments of the San Giovanni Battista-Molinette Hospital (431 cases) and S. Anna Hospital (522 cases) in Turin, Italy. Tumor slides were centrally reviewed by two of the authors (A.S., I.C.). Representative blocks were obtained and multicore tissue microarrays (TMAs) were prepared, as previously described [18] , using the advanced tissue arrayer (mod ATA-100, Chemicon International, Tamecula, CA, USA). Sections of the resulting recipient blocks were retested by IHC for ER status. Fifteen of 953 tumors were deemed ER-negative on TMAs and the negative results were further confirmed on whole tissue sections. These cases were excluded from the study (Fig. 1) . Clinical data of the remaining 938 patients including age, type of surgery, type of treatment, occurrence and type of relapse and current status were obtained from the Oncology Department of the two institutions. To confirm accuracy of previously recorded data, medical charts of all patients were reviewed. Pathological data including histotype, grade, and size of the tumors, peritumoral vascular invasion and stage were recorded according to the original diagnosis. The study was conducted in compliance with the ethical regulatory issues of the participating institutions.
Immunohistochemical procedure IHC was performed using an automated slide processing platform (Ventana BenchMark AutoStainer, Ventana Medical Systems, Tucson, AZ, USA) and the following primary antibodies: prediluted anti-ER rabbit monoclonal antibody (SP1, Ventana-Diapath, Tucson, AZ, USA); prediluted anti-PgR rabbit monoclonal antibody (1E2, Ventana-Diapath); anti-AR mouse monoclonal antibody (AR441, diluted 1:50, Dako, Glostrup, Denmark); antiKi67 monoclonal antibody (MIB1, diluted 1:100 Dako) and anti-HER2 polyclonal antibody (A0485, diluted 1:800, Dako). FISH assays for assessing HER2 gene amplification were performed for IHC equivocal (score 2?) cases, as previously reported [19] .
Positive and negative controls (omission of the primary antibody and IgG-matched serum) were included for each immunohistochemical run.
All TMAs slides were scanned by the Aperio system (ScanScope CS System, Vista, CA, USA) and automated counting was performed. To ensure the reliability of the automatic assessment all cases were reviewed on screen by two of the authors (A.S. and I.C.) blinded to patients' treatment assignment or outcome. If the recorded percentage of immunostained cells differed by more than 10%, then a collegial re-evaluation of the results was performed by three pathologists at the multiheaded microscope (I.C., R.A. and A.S.). This occurred for 1.2% of tumors. According to previous studies, the cut-off value for ER and PgR positivity was set at C1% and the same cut-off was also adopted for AR positivity [20] . The percentage of Ki67-positive cells was recorded and the cut-off for dichotomizing tumors with low and high proliferative fraction was established at 10% Fig. 1 Study flowchart shows the process for patient selection. ER estrogen receptor, TMA tissue micro array positive cells for the overall study population, and at 14% for sorting out luminal type B breast cancer as suggested by Cheang et al. [17] . HER2 status was classified as negative or positive (when scored 3? by IHC or HER2 amplified by FISH) according to the recommended guidelines for invasive carcinoma [21] .
Statistical analysis
Differences between AR-positive versus AR-negative tumors were analyzed by univariate analysis with the Chisquare or Fisher's exact test: P-values \0.05 were considered to be statistically significant.
Median follow-up time was calculated as the median observation time among all patients. Follow-up was censored at the time of death or the last clinical investigation of the patient.
Disease-specific survival (DSS) was calculated from the data of definitive surgery to the date of death of disease. Patients dying from other causes were censored at the time of death. Time to relapse (TTR) was measured from the data of definitive surgery to the data of first recurrence (defined as loco-regional or systemic). Contralateral breast cancer was not considered as relapse. The Kaplan-Meier method was used to estimate the TTR and DSS. The logrank test was used to test the survival differences.
Univariate analysis was used to examine what variables were associated with prognosis. Variables of interest included age, histotype, histological grade, pT and pN staging, vascular invasion, type of surgery (mastectomy versus breast conserving surgery), radiotherapy and chemotherapy. In order to adjust the risk estimate for potential confounders, a Cox proportional hazard regression for DSS and, TTR was used and hazard ratios (HR) were calculated. Multivariate analysis included variables significant at P \ 0.05 in univariate models or with a priori hypothesis for inclusion.
Statistical analysis was carried out using the SPSS version 17 (SPSS Inc, Chicago, IL) software, the R environment (www.r-project.org), SAS version 9.1 (SAS Institute, Cary, NC) and S-PLUS version 6.1 (Insightful Corp, Seattle, WA). This article was written in accordance with Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [22] .
Results
Patients' characteristics
The study cohort included 938 patients with tumors confirmed as ER positive. Clinical and histopathological features of the whole population are reported in Table 1 . The median follow-up time was 6.8 years. All patients were treated with endocrine therapy. The majority received tamoxifen as first option, 180 patients switched from tamoxifen to an aromatase inhibitor after 2 years. Using the local protocol (Online Resource 1) defined during the time period of this study (patient's age \50 years and tumor [2 cm in size and/or presence of lymph node metastases and/or presence of peritumoral vascular invasion), a cohort of 390 patients received both endocrine and chemotherapy.
Androgen receptor expression and outcome AR was assessable in 859 tumors and 609 (70.9%) of these were considered positive. As shown in Table 2 , AR positivity was associated with small tumor size (\2 cm), absence of lymph node metastases and PgR expression. Of the 250 AR-negative cases, 137 (54.8%) were treated with endocrine therapy only and 113 (45.2%) with endocrine and chemotherapy; of the 609 AR positive cases 358 (58.7%) were treated with endocrine therapy only and 251 (41.2%) with endocrine and chemotherapy.
Univariate analysis performed on the whole cohort of patients confirmed the correlation of the traditional histological and immunophenotypical factors with TTR (Table 3) and DSS (Table 4) . Focusing on AR expression, the 609 patients with AR-positive tumors had a better outcome (Fig. 2a, b ) (TTR: P = 0.001 and DSS: P \ 0.001). Then, we evaluated the effect of AR expression in the sub-cohort of patients treated with endocrine therapy alone. In this subset, the P-value of AR positivity was marginally significant at 0.046 for TTR (Table 3) and not significant for DSS (P = 0.247; Table 4 ; Fig. 3a) . By contrast, in the group of patients receiving endocrine and chemotherapy, AR positivity was a strong prognostic factor for both TTR (P = 0.015; Table 3 ) and DSS (P \ 0.001; Table 4 , Fig. 3b) . Following this result, we evaluated the effect of AR according to the different chemotherapeutic regimens, and we observed that AR expression was a marker of good prognosis in the group of patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF) (P = 0.001) and anthracycline (P = 0.018) (Fig. 3c, d) . While no such significance was demonstrated among subsets of patients receiving other types of chemotherapy, the numbers were limited and the data do not establish a reliable difference.
Cox multivariate analysis applied on the whole series of ER-positive cases for both TTR and DSS confirmed that AR status was an independent prognostic factor ( Table 5 ). The same role of AR was observed at Cox analysis for TTR, but not for DSS in patients treated with endocrine therapy alone (Table 6) , while AR remained an independent factor of good prognosis for both TTR and DSS in the group of patients treated with endocrine and chemotherapy, as did PgR and HER2 (Table 7) . However, a formal test for interaction between the use of chemotherapy and the expression of AR was not significant either for TTR (P = 0.66) or DSS (P = 0.21) (Fig. 4) , so this apparent difference needs to be interpreted with caution.
Androgen receptor expression and outcome in luminal type B breast cancer
To further explore the prognostic value of AR in ERpositive breast cancer with more aggressive biology that may be the target of chemotherapy, we selected a series of 343 cases classified on the basis of immunohistochemical markers as closely similar to the genetically defined luminal B, as recently proposed by Cheang et al. [17] . Briefly, we considered as luminal B HER2 positive tumors and HER2 negative tumors with Ki67 [14%.
Comparison of DSS and TTR of luminal type B against luminal A tumors confirmed poorer outcome among patients classified as luminal B (Fig. 3e) . Univariate analysis showed that the prognostic value on DSS of AR was maintained within the luminal B tumors (Fig. 3f) and Cox analysis confirmed this result for AR together with age, tumor size, vascular invasion and chemotherapy (Table 8) .
Discussion
In the present study on a large series of ER-positive breast cancers, AR expression, as evaluated by IHC, provides statistically significant prognostic value beyond established clinico-pathological parameters. The role of AR as a prognostic marker has been suggested by other authors, though there is a high variability in patient populations, assay methods, analysis of results, definitions used and reporting of results [3, [10] [11] [12] 23] . Particularly, the IHC cut-off values for positive and negative AR status are quite variable within different studies [3, 8] or are not reported at all [12] . In the present study, we used an automated system of analysis of IHC reactions that should avoid the bias of subjectivity linked to quantitative evaluation of IHC markers as performed by traditional microscopy. Using a cut-off of C1%, the AR expression rate in ER-positive breast cancer was of almost 71%, which is comparable with previous reports on breast cancer in general [4, 8] . If the cut-off was increased to C10%, the prevalence of positive cases would decrease to 60%, though the significant correlation with outcome is maintained (Online Resource 2). A possible bias of the present work might be the use of TMAs, but using the multicore procedure we have previously shown that hormone receptors-and in particular ER levels-are correctly evaluated without significant discrepancy as compared to whole section analysis [18] .
In addition, we showed that positive AR expression by IHC identifies patients with better prognosis within the subset of luminal type B tumors. Gene expression studies have identified two molecularly distinct subtypes of ERpositive breast cancers, the luminal types A and B, with luminal B tumors having poorer outcomes than luminal A tumors [14] [15] [16] . Recent studies have suggested that a combination of conventional IHC markers [17] may be considered a suitable surrogate for identifying a subset of breast cancers closely similar to the luminal B type defined by gene expression analysis. Our results show that in luminal type B cancers AR expression could be used as a prognostic marker, selecting a group of AR-positive tumors with better prognosis.
The likelihood of response of ER-positive breast cancers to adjuvant systemic chemotherapy cannot be accurately predicted, and the results of our retrospective study do not allow any conclusion that AR expression can predict which patients will benefit from the addition of chemotherapy, or indeed any particular type of chemotherapy, though the information that overall risk of relapse is lower in patients whose tumors express AR may assist decision-making in some cases. However, a recent study of triple negative breast cancers has shown by in vitro ATP-based chemotherapy response assay (ATP-CRA) that chemosensitivity to 5-fluorouracil and methotrexate was higher for tumors expressing AR and that this effect was not observed with other chemotherapeutics, such docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, oxaliplatin and paclitaxel [24] . Although a statistically significant interaction between chemotherapy and the expression of AR was not demonstrated, our results confirmed both by uni-and multivariate analysis a significant correlation of AR-positive immunoreaction and longer DSS in patients treated with any chemotherapeutic regimen containing CMF and also with regimens containing an anthracycline, while there was not a significant correlation of AR with survival in patients treated with taxanes or vinorelbine. On the other hand, recent experimental data suggest a role for AR overexpression as a novel mechanism of tamoxifen resistance and speculate that AR and ER could collaborate to regulate cyclin D1 gene expression, thereby promoting cell cycle progression in the presence of tamoxifen [25] . Taken together these data may suggest that AR/ER positive breast cancer with high KI67 expression could resist to tamoxifen therapy and benefit from specific chemotherapeutic treatment containing CMF and/or anthracyclines. Specific clinical trials and independent data set of patients with ERpositive disease who received chemo-endocrine therapy are needed to confirm this hypothesis.
The 2009 St. Gallen recommendations consider endocrine therapy indicated if any ER staining is present in the tumor [26] . One of the most difficult challenges in treating these patients, however, is the identification of patients with incompletely endocrine-responsive tumor who should receive a chemo-endocrine treatment. In prostate cancer, it has been suggested that knowledge of AR action in promoting cell proliferation can be used to design strategies that maximize cell death in response to cytotoxic therapy [27] . The results of the present study suggest that AR could be an important parameter for designing specific systemic treatments for the patients with ER-positive breast cancer. HR hazard ratio, CI confidence interval, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, AR androgen receptor 
